METABOLISM OF 2',3'-DIDEOXYINOSINE (DDI) IN HUMAN BLOOD

被引:29
作者
BACK, DJ
ORMESHER, S
TJIA, JF
MACLEOD, R
机构
[1] Department of Pharmacology and Therapeutics, University of Liverpool
关键词
DIDEOXYINOSINE; METABOLISM; BLOOD;
D O I
10.1111/j.1365-2125.1992.tb04043.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 2',3'-Dideoxyinosine (ddI) has potent activity against human immunodeficiency virus (HIV). It is converted within target cells to its active form dideoxyadenosine triphosphate(ddA-TP). 2 In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase. Since PNP is present in red blood cells we have examined the metabolism of [C-14]-ddI by human blood. 3 When incubated with whole blood at 37-degrees-C, ddI was extensively metabolised, principally to hypoxanthine (50.4 +/- 12.5% formed at 6 h; mean +/- s.d.; n = 16). Small amounts of uric acid were formed (3.8 +/- 2.4%). 4 ddI breakdown was temperature dependent, being virtually negligible at 4-degrees-C. Metabolism to hypoxanthine occurred within red blood cells. 5 The short half-life of ddI in patients is probably the result of both hepatic and erythrocytic metabolism.
引用
收藏
页码:319 / 322
页数:4
相关论文
共 17 条
[1]  
AGARWAL KC, 1975, BIOCHEMISTRY-US, V14, P79, DOI 10.1021/bi00672a013
[2]   INITIAL STUDIES ON THE CELLULAR PHARMACOLOGY OF 2',3'-DIDEOXYINOSINE, AN INHIBITOR OF HIV INFECTIVITY [J].
AHLUWALIA, G ;
COONEY, DA ;
MITSUYA, H ;
FRIDLAND, A ;
FLORA, KP ;
HAO, Z ;
DALAL, M ;
BRODER, S ;
JOHNS, DG .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (22) :3797-3800
[3]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR ANALYSIS OF 2',3'-DIDEOXYINOSINE IN HUMAN-BODY FLUIDS [J].
CARPEN, ME ;
POPLACK, DG ;
PIZZO, PA ;
BALIS, FM .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 526 (01) :69-75
[4]   INITIAL STUDIES ON THE CELLULAR PHARMACOLOGY OF 2',3'-DIDEOXYADENOSINE, AN INHIBITOR OF HTLV-III INFECTIVITY [J].
COONEY, DA ;
AHLUWALIA, G ;
MITSUYA, H ;
FRIDLAND, A ;
JOHNSON, M ;
HAO, Z ;
DALAL, M ;
BALZARINI, J ;
BRODER, S ;
JOHNS, DG .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (11) :1765-1768
[5]  
DOLIN R, 1990, REV INFECT DIS S5, V12, P540
[6]  
DU DL, 1989, P AM ASSOC CANC RES, V30, P606
[7]   PHARMACOKINETICS OF 2',3'-DIDEOXYADENOSINE AND 2',3'-DIDEOXYINOSINE IN PATIENTS WITH SEVERE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
HARTMAN, NR ;
YARCHOAN, R ;
PLUDA, JM ;
THOMAS, RV ;
MARCZYK, KS ;
BRODER, S ;
JOHNS, DG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :647-654
[8]  
Heinz F., 1983, METHOD ENZYMAT AN, P210
[9]   CHEMOTHERAPY OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS - CURRENT PRACTICE AND FUTURE-PROSPECTS [J].
HIRSCH, MS .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :845-857
[10]  
JOHNSON MA, 1988, J BIOL CHEM, V263, P15354